DIAGRAPH-PM Tablet
Glimeperide 2mg+ Pioglitazone Hcl 15mg + Metformin Hcl 500mg
Indication
*Type 2 diabetes (NIDDM)
*Hyperglycaemia
*Diabetic dyslipidemia
Glimepiride:
The rate of reduction of Hba(1c) was fastest in patients receiving glimepiride.
Superior action on blodd glucose level.
Glimepride does not show adverse effect on cardiac functions.
Pioglitazone:
Patients taking pioglitazone had relatively lower FPG.
Pioglitazone acts predominantly on nocturnal metabolism rather than at mealtimes.
FFA were reduced significantly in those taking pioglitazone (542.2 microEq/I vs.237.3 microEq/I; P < 0.01) before a decrease in HbA(1c) was apparent.
Favourable action on FPG and FFA(free fatty acid) of pioglitazone.
The complementary effects of pioglitazone with either metformin or an SU may also have the potential to preserve β-cell function and delay the progression of type 2 diabetes.
Metformin:
Improves glucose tolerance in patients with type 2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose.
Useful in reducing postprandial hyperglycaemia.
The insulin sensitizer, metformin, is mainly used in subjects with type 2 diabetes who are obese.